

COMPANY

Elanix Biotechnologies is striving to become a leader in regenerative medicine with innovative cell technologies focusing on **Advanced Wound Care, Advanced Skin Care and Cell Services**.

COMPANY VISION

Elanix aims to become a worldwide key player in **cell based regenerative medicine** for multiple clinical and non-clinical indications.

As a leader in regenerative medicine and tissue regeneration, Elanix is dedicated to commercialize innovative cell technologies and provide clinics, doctors, pharmacies, and patients with the best in-class **Advanced Wound Care and Skin Care** solutions.

Elanix will help millions of patients with needs for wound and skin care to accelerate the healing process with **more efficient, less painful and less expensive** medical solutions compared with current treatments.

COMPANY PROFILE

Elanix Biotechnologies develops and commercializes tissue regeneration products for Advanced Wound Care (acute and chronic), and Advanced Skin Care products for dermatological and gynecological applications. Additionally, Elanix provides services in cell therapy and related technologies. The Company evolved as a spin-off from the University Hospital of Lausanne (CHUV), Switzerland, in 2012 to commercialize a patented human progenitor cell technology platform.

Progenitor cells are fully differentiated yet immunologically privileged cells that are very potent inducers of tissue growth and healing. Elanix owns GMP-certified Master and Working human Cell Banks with vast quantities of cells. The Company has its registered office in Berlin, Germany, with an office in Wiesbaden and operational headquarters in Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F.

BUSINESS STRATEGY

Elanix pursues a threefold business strategy to commercialize the Elanix innovative cell technologies:

Advanced Skin Care (ASC) product launches 2017-2020 to leverage Elanix' progenitor cell and CFPC® technologies financing further AWC product developments.

Advanced Wound Care (AWC) product launches from 2020 on, being Elanix' future core product range.

Cell Services (Caas) using Elanix' own existing Cell Banks to possibly generate additional revenues with limited expenses.


ELANIX PRODUCTS BASED ON PROGENITOR CELLS

Advantages of progenitor cell technology

- Differentiated cells
- Potent growth factor
- Immunologically privileged
- Minimal culture requirements
- Easy handling in lyophilized form, no freezing required
- Significantly lower costs than current medical solution

Acting as catalyser for regeneration

- Promote healing
- Reduce pain
- Reduce scar tissue
- Improve skin elasticity



PRODUCT & DEVELOPMENT PIPELINE

Elanix will launch up to 6 ASC and 2 AWC products by 2020




ADVANCED WOUND CARE (AWC)

"First Cover", the company's lead acute and chronic Wound Care product portfolio, is being developed to provide protection and accelerated healing for burns and reconstructive surgery. Human progenitor skin cell based material is integrated as biotechnological product indicated for tissue regeneration in chronic and acute Wound Care.

Elanix is in the process of optimizing production of First Cover for randomized clinical evaluation for the treatment of 2nd degree burns. Patients with these burns usually require significant care to maintain hydration and prevent infection or, in case of hospitalized patients, reconstruction of tissue with grafting. A safety study of 24 patients with a 10-year follow-up was successfully carried out, as well as an ongoing compassionate use exemption program at CHUV Lausanne. First Cover has already been used to treat over 100 severe burn patients.

The AWC market is estimated at 6.9 BN USD with growth rates of 3-4% p.a.



ADVANCED SKIN CARE (ASC)

Elanix CFPC® Creams are innovative creams, based on animal progenitor cell derivatives, containing a proprietary Cell Free Protein Complex (CFPC®) which includes various proteins such as collagen, elastin and fibronectin.

GYNrepair®: Available on the market in Europe for gynecological application, GYNrepair is a CFPC® (Cell Free Protein Complex) cream specifically designed for use on the genital external mucosa to soothe the feeling of discomfort, twinges and dryness. Approximately 10-15% of all women seeking gynecological help suffer from intimate discomfort, soreness and dryness that result from several conditions, including vestibulodynia and vulvodynia.

SKINrepair®: Launch scheduled for Q4 2018. SKINrepair restores and reinforces the cutaneous barrier and soothes the present superficial lesions. The cream is formulated to correct skin irregularities, to moisturize and to help regenerate the epidermis. SKINrepair is intended to be used for sensitive or weakened skin with a tendency to irregularities.

Elanix will launch up to 4 further ASC products by 2020.

The worldwide ASC market size is estimated at 9.0 BN EUR.

CELLS AS A SERVICE (CaaS)

Elanix intends to further leverage its human progenitor cell banks through the provision of CaaS for pharmaceutical and cosmetic research applications. In addition, CaaS will selectively be provided to hospitals and clinics for autologous treatments.

ELANIX IS TARGETING TO ACHIEVE BREAK EVEN IN 2020



MANAGEMENT TEAM

Tomas Svoboda, BSc., MBA Chief Executive Officer
Egon Minar, Mag. Chief Operating Officer & Chief Financial Officer
Geoffrey De Visscher, PhD, MBA Chief Technology Officer
Franck Waechter Business Head Advanced Skin Care

SUPERVISORY BOARD

Jürgen F. Kullmann Chairman
Marc Voigt Vice-Chairman
Abigael De Buys Roessingh

FOUNDERS AND SCIENTIFIC ADVISORS

Prof. Lee-Ann Laurent Applegate, PhD
Prof. Wassim Raffoul MD, PhD, Msc., FCIRSE
Anthony De Buys Roessingh MD, PhD, PD, Senior Lecturer
Nathalie Hirt-Burri PhD
Corinne Scaletta

DISCLAIMER

This company overview contains forward-looking statements subject to certain risks and uncertainties. Actual results may be materially different from those expressed or implied by such statements due to a variety of risk factors and uncertainties such as changes in the business, economic and competitive situation, exchange rate fluctuations, uncertainties regarding litigation or investigation proceedings and the availability of financial resources. This company overview does not constitute an offer or invitation to subscribe for or purchase any securities of Elanix Biotechnologies AG.

The information contained in this company overview is not for publication or distribution in or into the United States of America, Australia, Canada or Japan.

This company overview does not constitute a prospectus within the meaning of the EU directive 2003/71/EC of the European Parliament and of the council of 4 November 2003 as amended ("prospectus directive") and Elanix will not prepare such prospectus for this capital increase.

Elanix Biotechnologies SA
Chemin du Joran 10 . 1260 Nyon 2 . Switzerland
T +41 22 363 66 40 F +41 22 363 66 41
info@elanix-bt.com . www.elanixbiotechnologies.com

Elanix Biotechnologies AG
Hohenstaufenstrasse 1 . 65189 Wiesbaden . Germany
T +49 611 7162 76 77 F +49 611 7169 27 54
info@elanix-bt.com . www.elanixbiotechnologies.com